K
Keith A. Baggerly
Researcher at University of Texas MD Anderson Cancer Center
Publications - 193
Citations - 59407
Keith A. Baggerly is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 65, co-authored 192 publications receiving 50803 citations. Previous affiliations of Keith A. Baggerly include University of Texas Health Science Center at Houston & Harvard University.
Papers
More filters
Journal ArticleDOI
Identifying differentially expressed genes in cDNA microarray experiments.
Keith A. Baggerly,Kevin R. Coombes,Kenneth R. Hess,David N. Stivers,Lynne V. Abruzzo,Wei Zhang +5 more
TL;DR: This work derives models for the intensity of a replicated spot, when replication is performed within and between arrays, and predicts how the variance of a log ratio changes with the total intensity of the signal at the spot, independent of the identity of the gene.
Journal ArticleDOI
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Lajos Pusztai,Betsy Gregory,Keith A. Baggerly,Bo Peng,John M. Koomen,Henry Mark Kuerer,Francisco J. Esteva,W. Fraser Symmans,Peter Wagner,Gabriel N. Hortobagyi,Christine Laronga,O. John Semmes,George L. Wright,Richard R. Drake,Antonia Vlahou +14 more
TL;DR: Proteomic changes were examined in response to paclitaxel chemotherapy or 5‐fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in plasma from patients with Stage I–III breast carcinoma.
Journal ArticleDOI
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Charles C. Guo,Vipulkumar Dadhania,Li Zhang,Tadeusz Majewski,Jolanta Bondaruk,Maciej Sykulski,Weronika Wronowska,Anna Gambin,Yan Wang,Shizhen Zhang,Enrique Fuentes-Mattei,Ashish M. Kamat,Colin P.N. Dinney,Arlene O. Siefker-Radtke,Woonyoung Choi,Keith A. Baggerly,David J. McConkey,John N. Weinstein,Bogdan Czerniak +18 more
TL;DR: Micropapillary cancer evolves through the luminal pathway and is characterized by the activation of miR-296 and RUVBL1 target genes and represents the most aggressive molecular subtype of the disease with the shortest survival.
Journal ArticleDOI
FABP4 as a key determinant of metastatic potential of ovarian cancer
Kshipra M. Gharpure,Sunila Pradeep,Sunila Pradeep,Marta Sans,Rajesha Rupaimoole,Cristina Ivan,Sherry Y. Wu,Emine Bayraktar,Archana S. Nagaraja,Lingegowda S. Mangala,Xinna Zhang,Monika Haemmerle,Wei Hu,Cristian Rodriguez-Aguayo,Michael McGuire,Celia Sze Ling Mak,Xiuhui Chen,Michelle A. Tran,Alejandro Villar-Prados,Guillermo N. Armaiz Pena,Ragini Kondetimmanahalli,Ryan Nini,Pranavi Koppula,Prahlad T. Ram,Jinsong Liu,Gabriel Lopez-Berestein,Keith A. Baggerly,Livia S. Eberlin,Anil K. Sood +28 more
TL;DR: In this article, the authors explored the underlying mechanisms that could increase metastatic potential in ovarian cancer and found that fatty acid binding protein (FABP4) can substantially increase the metastasis potential of cancer cells.
Journal ArticleDOI
Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland
Tiina Suominen,Linda L. Bachinski,Satu Auvinen,Peter Hackman,Keith A. Baggerly,Corrado Angelini,Leena Peltonen,Ralf Krahe,Bjarne Udd +8 more
TL;DR: DM2 appears more frequent than DM1, with most DM2 patients currently undiagnosed with symptoms frequently occurring in the elderly population, and the identification of DM2 mutations in NMD patients with clinical phenotypes not previously associated with DM2 is of particular interest.